Version 1
: Received: 14 July 2023 / Approved: 14 July 2023 / Online: 14 July 2023 (09:30:25 CEST)
Version 2
: Received: 17 July 2023 / Approved: 18 July 2023 / Online: 18 July 2023 (07:17:24 CEST)
San Francisco, I.F.; Rojas, P.A.; Bravo, J.C.; Díaz, J.; Ebel, L.; Urrutia, S.; Prieto, B.; Cerda-Infante, J. Can We Predict Prostate Cancer Metastasis Based on Biomarkers? Where Are We Now? Int. J. Mol. Sci.2023, 24, 12508.
San Francisco, I.F.; Rojas, P.A.; Bravo, J.C.; Díaz, J.; Ebel, L.; Urrutia, S.; Prieto, B.; Cerda-Infante, J. Can We Predict Prostate Cancer Metastasis Based on Biomarkers? Where Are We Now? Int. J. Mol. Sci. 2023, 24, 12508.
San Francisco, I.F.; Rojas, P.A.; Bravo, J.C.; Díaz, J.; Ebel, L.; Urrutia, S.; Prieto, B.; Cerda-Infante, J. Can We Predict Prostate Cancer Metastasis Based on Biomarkers? Where Are We Now? Int. J. Mol. Sci.2023, 24, 12508.
San Francisco, I.F.; Rojas, P.A.; Bravo, J.C.; Díaz, J.; Ebel, L.; Urrutia, S.; Prieto, B.; Cerda-Infante, J. Can We Predict Prostate Cancer Metastasis Based on Biomarkers? Where Are We Now? Int. J. Mol. Sci. 2023, 24, 12508.
Abstract
Background: The incidence of prostate cancer (PC) has been risen annually. Despite the diagnosis is made mainly with non-metastatic PC, mortality is explained by the metastatic disease (mPC). Without a doubt there is an intermediate scenario in which patients have no mPC but will have initiated a metastatic cascade through an epithelial-mesenchymal transition. There is indeed a need for more and better tools to predict what patients will progress in the future to non-localized clinical disease or already have micrometastatic disease, and therefore, will clinically progress after primary treatment. Biomarkers for predicting mPC are still under development; there are few studies and not much evidence of their usefulness. Summary: This review is focused on tissue-based genomic biomarkers (TBGB) for predicting metastatic disease. We developed four main research questions that will attempt to answer according to the current evidence. Why is important to predict metastatic disease? Which tests are available to predict metastatic disease? What impact should there be on clinical guidelines and clinical practice in predicting metastatic disease? What are current prostate cancer treatments? Key Messages: Knowing useful predict tools could help determine which patients may need multimodal or adjuvant treatment even with a localized disease, and in consequence, what patients do not need more than a single modality of treatment. The importance of predicting metastasis is fundamental, given that once metastasis is diagnosed, the quality of life (QoL) and survival drop dramatically.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
,
,
,
*,*
Commenter: Ignacio F San Francisco
Commenter's Conflict of Interests: Author
We changed a name of the coi. It said Benjain and now is Benjamín